Development of Daptomycin‐Susceptible, Methicillin‐Resistant<i>Staphylococcus aureus</i>Pneumonia during High‐Dose Daptomycin Therapy

Koplowicz, Yelena B.; Schwartz, Brian S.; Guglielmo, B. Joseph

doi:10.1086/605690

Cited by 5 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Daptomycin is inactivated by lung surfactant . Clinical trials for the treatment of pneumonia showed that daptomycin failed to show non‐inferiority against comparators , and breakthrough pneumonia due to daptomycin‐susceptible strains may appear during treatment with daptomycin . As several meta‐analyses from clinical trials have reported an increased mortality for tigecycline vs. comparators , we do not recommend this drug for the treatment of monomicrobial infections with VRE.…”

Section: Mdr Pathogens In Solid Organ Transplant Recipientsmentioning

confidence: 97%

Multidrug-resistant bacteria in solid organ transplant recipients

Cervera

Delden

Gavaldá

et al. 2014

Clinical Microbiology and Infection

146

111

View full text Add to dashboard Cite

Bacteria are the leading cause of infections after solid organ transplantation. In recent years, a progressive growth in the incidence of multidrug-resistant (MDR) and extensively-drug-reistant (XDR) strains has been observed. While methicillin-resistant Staphylococcus aureus (MRSA) infection is declining in non-transplant and SOT patients worldwide, vancomycin-resistant enterococci, MDR/XDR Enterobacteriaceae and MDR/XDR non-fermenters are progressively growing as a cause of infection in solid organ transplant (SOT) patients and represent a global threat. Some SOT patients develop recurrent infections, related to anatomical defects in many cases, which are difficult to treat and predispose patients to the acquisition of MDR pathogens. As the antibiotics active against MDR bacteria have several limitations for their use, which include less clinical experience, higher incidence of adverse effects and less knowledge of the pharmacokinetics of the drug, and, in most cases, are only available for parenteral administration, it is mandatory to know the main characteristics of these drugs to safely treat SOT patients with MDR bacterial infections. Nonetheless, preventive measures are the cornerstone of controlling the spread of these pathogens. Thus, applying the Center for Disease Control and Prevention's and the European Society of Clinical Microbiology and Infectious Diseases's recommended antibiotic policies and strategies to control the transmission of MDR strains in the hospital setting is essential for the management of SOT patients.

show abstract

Section: Mdr Pathogens In Solid Organ Transplant Recipientsmentioning

confidence: 97%

Multidrug-resistant bacteria in solid organ transplant recipients

Cervera

Delden

Gavaldá

et al. 2014

Clinical Microbiology and Infection

146

111

View full text Add to dashboard Cite

show abstract

“…Furthermore, linezolid is bacteriostatic and its long-term use (e.g., >2 weeks) has been associated with the development of peripheral neuropathy, lactic acidosis, and thrombocytopenia (as well as the potential for trilineage bone marrow suppression) 10. Daptomycin lacks pulmonary activity, and may cause a pulmonary hypersensitivity reaction and myopathy 11,12. Additionally, daptomycin resistance has been noted in the setting of prior vancomycin therapy, especially with suboptimal dosing and sequestered infections including osteomyelitis, endocarditis, and device related infections 13–16.…”

Section: Introductionmentioning

confidence: 99%

Ceftaroline: A New Cephalosporin with Activity Against Methicillin-Resistant Staphylococcus aureus (MRSA)

Duplessis

Crum-Cianflone

2011

Clinical Medicine Reviews in Therapeutics

View full text Add to dashboard Cite

Microbial resistance has reached alarming levels, threatening to outpace the ability to counter with more potent antimicrobial agents. In particular, methicillin-resistant Staphylococcus aureus (MRSA) has become a leading cause of skin and soft-tissue infections and PVL-positive strains have been associated with necrotizing pneumonia. Increasing reports of growing resistance to glycopeptides have been noted, further limiting the efficacy of standard antibiotics, such as vancomycin. Ceftaroline is a novel fifth-generation cephalosporin, which exhibits broad-spectrum activity against Gram-positive bacteria, including MRSA and extensively-resistant strains, such as vancomycin-intermediate S. aureus (VISA), heteroresistant VISA (hVISA), and vancomycinresistant S. aureus (VRSA). In addition to being an exciting new agent in the anti-MRSA armamentarium, ceftaroline provides efficacy against many respiratory pathogens including Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Ceftaroline (600 mg intravenously every 12 hours) has been shown effective in phase III studies in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia. To date, this unique antibiotic exhibits a low propensity for inducing resistance and has a good safety profile, although further post-marketing data and clinical experience are needed. In summary, ceftaroline provides an additional option for the management of complex multidrug resistant infections, including MRSA.

show abstract

“…Although a prospective study of 1092 patients with complicated skin infections did not demonstrate that daptomycin caused pulmonary adverse effects more than penicillinase-resistant penicillins and vancomycin [2], there have been a few case reports of serious pulmonary complications associated with daptomycin published recently [3][4][5][6][7]. The exact mechanism of lung injury and associated eosinophilia is unknown.…”

mentioning

confidence: 99%